Inhaled sirolimus trial aims to ease breathing in lung scar patients
NCT ID NCT05798923
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This Phase 2 trial tests an inhaled drug called LAM-001 (sirolimus) in 85 adults who have pulmonary hypertension (high blood pressure in the lungs) along with interstitial lung disease (lung scarring). The study compares the drug to a placebo to see if it improves blood flow in the lungs and is safe to use. Researchers will also check if it helps patients walk farther and delays worsening of their condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LAM-001 (inhaled sirolimus)
- What this could lead to
- If successful, this could point toward a new treatment option for people with pulmonary hypertension caused by lung scarring, potentially improving exercise ability and slowing disease worsening.
- What could go wrong
- This is an early Phase 2 trial with only 85 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects like lung irritation or worsening of underlying lung disease are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION DUE TO LUNG DISEASES AND HYPOXIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
Contact
Contact Email: •••••@•••••
-
University of Arizona
RECRUITINGTucson, Arizona, 85748, United States
Contact
Contact Email: •••••@•••••
-
Yale New Haven Hospital
NOT_YET_RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.